Recent articles

Over the last 15 years, a large number of so-called ‘biosimilars’ have been marketed. Biosimilars are biological drugs that have been copied from the biological reference drug after the period of ...

Two new drugs for the acute treatment of migraine attacks were authorised in 2022. They concern the ‘calcitonin gene-related peptide’ (CGRP) antagonist rimegepant, which was previously discussed i ...

The sodium-glucose cotransporter two (SGLT2) inhibitors dapagliflozin and empagliflozin have recently been authorised for use in patients with chronic symptomatic heart failure. After the rapid gr ...

In recent years, it has become customary in the treatment of chronic spontaneous urticaria (CSU) to prescribe second-generation antihistamines in dosages higher than the authorised dosage. The eff ...

The end of the COVID pandemic is not yet in sight, despite the increased immunity among the public from vaccination or infections. Knowledge about the treatment of COVID-19 has grown, and dexameth ...

Daridorexant is a new sleep medication with a different mode of action than, for instance, benzodiazepine. Daridorexant is a so-called dual orexin receptor antagonist (DORA), which within the comp ...

The slimming product Mysimba®, a combination of naltrexon and bupropion, was recently included in the Dutch drug reimbursement system (Geneesmiddelenvergoedingssysteem, GVS). The drug is fully rei ...

Two million people in the Netherlands regularly experience migraine. In addition to preventive medication, a large proportion of patients also use drugs for the acute treatment of a migraine attac ...